00:00 are encouraging results of a recent clinical trial where over 44% of patients who received
00:06 a therapeutic vaccine for lung cancer were still alive one year after receiving the treatment.
00:13 To tell us a bit more Shirley Sipvon from our science desk is with me and Shirley this
00:17 was a trial carried out here in France just tell us a bit more about what the medics found.
00:22 So once again it's tailor-made let's see we have a graphic showing that it all starts
00:29 with the sequencing of the tumor cells the tumor tissues which are taking taken out of
00:35 the body and they're analyzed and then artificial intelligence is used to identify the 30 most
00:42 likely mutations and then a vaccine is created out of that data analyzed by artificial intelligence
00:51 because there could be thousands of mutations but it identified only 30 and then a vaccine
00:56 is made once the vaccine is created well it sends a signal to the immune system it tells
01:01 the T cells how to recognize and destroy the tumor cells which is quite extraordinary and
01:09 these are some illustrations of obviously the fight against lung cancer the idea is
01:12 they want to develop this to various other cancers as well many companies are working
01:17 on this and you talked about the survival rate so two groups were taken a year ago one
01:22 had chemotherapy the other one had this vaccine all of them were people who already had this
01:27 lung cancer and the group who took the vaccine who had the vaccine several times well it
01:33 survived 44% survived after one year and the other group only 27.5% survived so it shows
01:41 a real difference also the second side effects were also lessened so there's great hope in
01:48 that how many vaccines did they have first was every three weeks then every two months
01:52 and every three months and the testing will continue the goal is to develop this type
01:58 of therapeutic vaccine and as we've said various companies are working and targeting various
02:04 cancers this type is lung cancer all right really promising research indeed Shelley Sitbon
02:09 thanks very much
02:10 [BLANK_AUDIO]
Comments